Document Detail

ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine).
MedLine Citation:
PMID:  22896808     Owner:  NLM     Status:  MEDLINE    
On June 10th, 2011, the U.S. Food and Drug Administration approved Potiga (ezogabine) as an add-on medication for the treatment of seizures in adults, and it is being developed by Valeant Pharmaceuticals.
Corey R Hopkins
Related Documents :
18458868 - Coming out of the woods: do termites need a specialized worker caste to search for new ...
17294428 - First evidence for relocation of stationary food resources during foraging in a strepsi...
14749818 - Olfaction: scent-triggered navigation in honeybees.
15584778 - Following and joining the informed individual in semifree-ranging tonkean macaques (mac...
17993218 - Energy, food, and land-- the ecological traps of humankind.
12940418 - Exopeptidases and their application to reduce bitterness in food: a review.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  ACS chemical neuroscience     Volume:  3     ISSN:  1948-7193     ISO Abbreviation:  ACS Chem Neurosci     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-16     Completed Date:  2013-04-10     Revised Date:  2013-08-18    
Medline Journal Info:
Nlm Unique ID:  101525337     Medline TA:  ACS Chem Neurosci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  632     Citation Subset:  IM    
Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology and Chemistry, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee 37232-6600, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticonvulsants / pharmacology*,  therapeutic use
Carbamates / pharmacology*,  therapeutic use
Epilepsy / drug therapy
KCNQ Potassium Channels / agonists
Phenylenediamines / pharmacology*,  therapeutic use
Potassium Channels / agonists
Randomized Controlled Trials as Topic
Seizures / prevention & control
United States
United States Food and Drug Administration
Reg. No./Substance:
0/Anticonvulsants; 0/Carbamates; 0/KCNQ Potassium Channels; 0/Phenylenediamines; 0/Potassium Channels; 12G01I6BBU/ezogabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Unparalleled control of neural activity using orthogonal pharmacogenetics.
Next Document:  Arachidonic acid enhances caffeine-induced cell death via caspase-independent cell death.